Sandoz wins Canadian approval for generic semaglutide
The Sandoz version is cleared in Canada as the country's semaglutide patent position opens, with the company framing the move as expanding access.
DO
By Daniel Okafor · Regulatory Correspondent
Sep 18 01:21 ETSource: Sandoz
The wire
- 01Sandoz said it received Canadian regulatory approval for a generic semaglutide, its first approval for a generic version of the GLP-1 medicine.
- 02Generic entry in Canada creates a licensed, lower-cost alternative to brand semaglutide and a reference point for pricing pressure in other markets.
- 03Launch timing, pricing and which indications the approval covers were not detailed in the announcement.
From the source
Read at sandoz.comSandoz receives regulatory approval for generic semaglutide in Canada, paving way to expand patient access to key GLP-1 medicine
